Advocacy intelligence hub — real-time data for patient organizations
Shanghai Jiao Tong University Affiliated Sixth People's Hospital — PHASE4
Tang Xiaodong — PHASE1, PHASE2
Peking University People's Hospital — NA
Amgen — PHASE4
Shanghai JMT-Bio Inc. — PHASE3
Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE2
St. Louis University — PHASE3
XGEVA: FDA approved
Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
XGEVA
Amgen, Inc.
XGEVA
(denosumab)Orphan drugAmgen, Inc.
RANK Ligand Inhibitor [EPC]
12.1 Mechanism of Action Xgeva binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, ...
Changye Zou, MD
First Affiliated Hospital, Sun Yat-Sen University
Amir A Jazaeri, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Jessica Gartrell, MD, MD
St. Jude Children's Research Hospital
📍 MEMPHIS, TN
Scott Schuetze, MD, PhD, MD, PhD
University of Michigan
📍 ANN ARBOR, MI
Davide Donati, MD
Istituto Ortopedico Rizzoli
Vishruth Reddy, MD, PhD, M.D., Ph.D
UCLA / Jonsson Comprehensive Cancer Center
📍 LOS ANGELES, CA